Humanised anti-TNFα Fab' fragment conjugated to a 40 kDa branched polyethylene glycol (PEG) moiety. Lacks the IgG Fc region → no complement activation, no antibody-dependent cytotoxicity, and importantly no FcRn-mediated transplacental transfer (preferred anti-TNF during pregnancy). PEGylation extends half-life and reduces immunogenicity compared to native Fab'.
Half-Life & Elimination Curve (SC: 14d)
Elimination (SC)
0×t½0h100%(50.8 mg/L)
1×t½14d50%(25.4 mg/L)
2×t½28d25%(12.7 mg/L)
3×t½42d12.5%(6.35 mg/L)
4×t½56d6.3%(3.17 mg/L)
5×t½70d3.1%(1.59 mg/L)
Elimination t½14d (SC)
Rate Constant (ke)0.00206 h⁻¹
Est. Peak (Cmax)50.8 mg/L
Clearance (CL)0.013 L/h
97% Washout (5×t½)70d
Dosing Guidelines
Subcutaneous (SC): Typical 400 mg
Pharmacokinetic Parameters
Subcutaneous (SC): Bioavailability (F): 80% · Volume of Distribution (Vd): 6.3 L [PMID 25586216]